Parcell Laboratories Promotes Colin White, Ph.D., To Chief Scientific Officer

Parcell Laboratories, Inc., developer of novel therapeutics based on its patented adult stem cell platform technology, the ELA® cell, has promoted Colin White, Ph.D., to the newly-created position of chief scientific officer. Dr. White led the company's research and development efforts prior to the promotion, which is effective immediately. Dr. White joined Parcell Laboratories in 2012.

"We are very fortunate to have Dr. White on our team," said Pamela Layton, founder and CEO of Parcell Laboratories. "His contributions to Parcell Labs have helped us advance our efforts in the development of novel proprietary cell therapies around our ELA stem cell platform technology. His understanding of clinical product development best practices is helping us successfully transition potential products from basic research all the way through manufacturing, and onwards to pre-clinical and clinical development."

"Cell therapy has demonstrated tremendous potential to improve the lives of patients suffering from numerous medical conditions," said Dr. White. "I am excited to assume this role at Parcell as the company pursues several promising product candidates that will take us closer to achieving true disease reversal. Parcell intends to go well beyond simple palliative care by manufacturing innovative and efficacious therapeutics for spinal fusion, the treatment of acute and chronic cartilage injuries, and the rejuvenation of damaged skin. My team is extremely dedicated to unlocking the future of cell therapy, and I believe that Parcell is well-positioned to play a prominent role in ushering in this next generation of truly personalized medicine."

Prior to joining Parcell Labs, Dr. White served as an instructor in pathology at Beth Israel Deaconess Medical Center and Harvard Medical School. He was named a research fellow at Brigham and Women's Hospital and Harvard Medical School in 2008. Since 2005, Dr. White has also served as a mentor for young scientists who wish to transition out of academia. He passionately believes that these individuals are often guilty of not recognizing their true achievements and how to highlight these successes appropriately, something he says that he tries to remedy by regularly speaking at science career events held at multiple institutions in the Greater Boston area.

Dr. White is a featured speaker at many industry events, including the upcoming New York Stem Cell Summit '14 on February 18 and the Global Technology Community's Cell & Gene Therapy Conference in San Diego on February 20. He has also described his work in textbooks and peer-reviewed journals, including: Current Protocols of Molecular Biology, Cell Signaling, the Biochemical Journal, the Journal of Biological Chemistry, Molecular Endocrinology, FEBS Letters, Methods in Molecular Biology, and Neuroendocrinology. In addition, Dr. White regularly serves as a peer reviewer for several high-impact publications.

About Parcell Laboratories

Parcell Laboratories, Inc., founded in 2008, develops novel therapeutics based on its patented adult stem cell platform technology, the ELA® cell. The ELA cell was discovered by scientists affiliated with the Brigham and Women's Hospital and Harvard Medical School, who demonstrated the vast potential of the technology in regenerative medicine. ELA cells are found in various tissues throughout the body and are characterized by a specific surface marker profile that set them apart from other adult stem cells. Based in Natick, Mass., the company's state-of-the-art research, processing, storage and fulfillment facilities set the stage for the future of adult stem cells and regenerative medicine. For more information, visit www.parcelllabs.com. Parcell Laboratories is a member of the Parcell Group of companies, which also includes CellCure Trust LLC and Cellogx, LLC.